Levetiracetam Arrow Lab

Levetiracetam, the active ingredient in Levetiracetam Arrow Lab, is an antiepileptic presented as a tablet for oral use. It is indicated for the treatment of partial, generalized tonic‑clonic and myoclonic seizures in patients diagnosed with epilepsy.

GNH USA supplies Levetiracetam Arrow Lab as a licensed, GDP‑compliant international pharmaceutical supplier, providing EU‑sourced medication to hospitals, pharmacies and clinics worldwide while adhering to stringent quality and regulatory standards, supporting global healthcare delivery.

Levetiracetam is an antiepileptic drug that reduces seizure activity across several seizure types.

Partial seizures: helps control focal onset seizures, reducing frequency and severity. Generalized tonic‑clonic seizures: provides seizure control for primary generalized convulsions. Myoclonic seizures: decreases rapid, involuntary muscle jerks associated with myoclonic epilepsy. Adjunct therapy: can be used as add‑on treatment when other antiepileptics are insufficient.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Drowsiness - Dizziness - Headache - Irritability

Serious or Rare Side Effects: - Severe allergic reactions (e.g., Stevens‑Johnson syndrome) - Psychiatric disturbances (e.g., depression, suicidal thoughts) - Blood disorders (e.g., neutropenia, thrombocytopenia)

When prescribing levetiracetam, clinicians should consider several safety measures.

Renal function: adjust dose in patients with impaired renal clearance. Mood changes: monitor for irritability, depression or suicidal ideation. Abrupt discontinuation: taper gradually to avoid seizure worsening. Pregnancy: evaluate risk‑benefit as data are limited. Drug interactions: review concomitant antiepileptics and enzyme inducers. Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Levetiracetam has a relatively low interaction profile, but certain co‑medications may affect its efficacy or safety.

Major Interactions (Avoid): - Alcohol: may increase central nervous system depression. - Other CNS depressants: concurrent use can potentiate sedation.

Moderate Interactions (Monitor Closely): - Carbamazepine: enzyme inducer that can lower levetiracetam plasma levels. - Phenobarbital: may reduce levetiracetam concentrations. - Rifampin: may decrease levetiracetam exposure.